alprazolam note article came psychiatric times today edited version i posting unedited version provide details i seen printed version yet i add link later download pdf version past years widely discrepant views use benzodiazepines table varying avoiding use entirely moderate high dose maintenance benzodiazepines certain anxiety disorders reviews early st century suggested high potency benzodiazepines preferred agents treating anxiety disorders panic disorder due rapid onset action fact older low potency benzodiazepines considered ineffective panic disorder reviews discussed side effects due tolerance rebound anxiety direct effects memory dependence time frame treatment guidelines treating anxiety disorders recommended shorter periods use benzodiazepines longer regarded first line treatment parallel evolution thought addictive potential benzodiazepines ranging view low abuse potential current observations benzodiazepines frequently seen used combination drugs abuse commonly seen polydrug overdose scenarios benzodiazepines schedule iv compounds according controlled substances means group low potential abuse despite assessment alprazolam third common diverted drug epidemiology practical data extent use benzodiazepines population available national survey drug use health nsduh samhsa recent data breaks benzodiazepine preparations compounds million people population used benzodiazepine tranquilizers group million population used alprazolam containing products additional category sedatives designated million sedative users sixty percent sedative users used zolpidem type sedatives represented million people population million population used benzodiazepine type sedatives nsduh survey estimates degree misuse addition total use total million people estimated misused sedatives group million misused benzodiazepines group million population misused alprazolam additional million people misused zolpidem products misused benzodiazepine sedatives specific estimates misuse individual products terms total number percentage population included report survey estimates use misuse benzodiazepines give measure morbidity mortality measures available pharmacovigilance projects project years england wales reported group patients sustained severe harm death medication related incidents benzodiazepines ranked sixth opioids antibiotics warfarin heparin insulin recent report centers disease control cdc analyzed drugs frequently involved overdoses years two top ten drugs involved overdoses benzodiazepines diazepam alprazolam deaths involving diazepam alprazolam involved use concomitant drugs fatal opioid overdoses involve benzodiazepines cdc fda developed prescription behavior surveillance system pbss look trends prescriptions controlled substances pbss categorizes data three categories benzodiazepines stimulants opioid analgesics zolpidem classified miscellaneous category rather benzodiazepines system benzodiazepine prescribing rates noted vary prescriptions per residents highest rates occurred patient segment years age greater number overlapping days treatment benzodiazepines opioids varied study illustrates common problems benzodiazepine prescribing geriatric patients patients maintained opioids well benefits pharmacovigilance system clinical guidelines guidelines benzodiazepine use evolved years series texts like principles practice psychopharmacology provides idea authors conclusions reviewing literature updates publication dates ranging authors text provide algorithmic summary anxiety disorders based severity chronicity examining successive chapters treatment panic disorder benzodiazepines reserved inadequate response behavior therapy selective serotonin reuptake inhibitor ssri plus behavior therapy tricyclic antidepressants tca behavior therapy point initial recommendation alprazolam clonazepam entry point algorithm severe level authors recommended alprazolam plus tca ssri first month insufficient indefinite alprazolam additional therapies without benzodiazepines level treatment inadequate second edition clonazepam added algorithm another option refractory anxiety subsequent editions antidepressant venlafaxine tca alprazolam xr serotonin norepinephrine reuptake inhibitors snri anticonvulsant valproate gabapentin factored decision points basic position benzodiazepines unaltered limited use first month ssri starts work preferred unless insufficient response case benzodiazepines added level various therapies maintenance therapy insufficient response opinions available specialty texts treatment anxiety disorders one sources treatment panic disorder echoes janicak et al text listing ssri snri antidepressants cognitive behavioral therapy first line treatment benzodiazepines listed treatment refractory cases long list options standard psychiatric references list benzodiazepines first line treatment anxiety disorders using example generalized anxiety disorder typical problems described include need frequent dosing rebound anxiety difficulty transitioning medication inability address comorbid depressive states cognitive side effects one property mentioned non addiction literature subgroup patients benzodiazepines reinforce self administration occur number ways patients notice either euphorigenic calming effect reinforcing calming effect occurs case social anxiety disorder effect drug secondary effects social affiliation reinforcing case patients phobias medication take magical talisman effect person may find difficult confront feared situation medication needs possession whether take important understudied aspects behavioral pharmacology benzodiazepines additional consideration use benzodiazepines problem chronic use anxiety disorders chronic conditions studies show subgroups require pharmacotherapy part time intervals initial diagnosis objective guidance receive indefinite maintenance therapy decision complicated several potential problems short term tolerance dose escalation occur behavioral pharmacology issues previously mentioned part dose escalation complicate plan stopping point benzodiazepines also complicate use medications notably opioids social drinking problem person maintained benzodiazepines increasing concern geriatric complications including falls cognitive impairment cohort benzodiazepine treatment ages several patterns benzodiazepine use addictive disorders explain drugs frequently found secondary medications moderate heavy drinkers frequently wake middle night withdrawal additional withdrawal symptoms morning benzodiazepines sleep medications taken maintain sleep treat early morning withdrawal symptoms opioid users use benzodiazepines treat withdrawal also several studies suggest benzodiazepines used augment effect opioids attempt create euphorigenic effect including methadone maintenance stimulant users obtain benzodiazepines stop continuous insomnia associated stimulant use one groups uses intoxicants primarily amnestic effect use benzodiazepines number agents induce intoxication delirium escape perceived stressors scenarios important assess person secondary use benzodiazepines discuss high risk created despite long term concerns behavioral pharmacology related concerns benzodiazepines indispensable medications number situations first line medications catatonia inpatient settings greatly reduce morbidity associated condition used inpatient settings treating acute agitation associated manic psychotic states also used various forms anesthesia benzodiazepines preferred medications detoxification alcohol sedative hypnotic drugs due wide safety margin acute dosing doubt supervised setting medications clearly preferred agents conditions quality concern length stay considerations play important part uses inpatient physician may find patient discharged benzodiazepine tapered discontinued case plan needs developed clear patient take medication controlled manner table lists number applications patients substance use problems purely diagnostic perspective treatment substance use disorders sud complicates assessment treatment co occurring psychiatric disorders several levels comorbidity anxiety depression substance use disorder high recent study looking pooled odds ratios across carefully selected studies showed strong associations alcohol dependence ci drug dependence ci major depression anxiety disorders associations alcohol dependence ci drug dependence ci recent study looking dsm criteria month drug use disorders found associations bipolar disorder dysthymia major depressive disorder posttraumatic stress disorder looking lifetime estimates added additional associations anxiety disorders including generalized anxiety disorders panic disorder social phobia studies generally based cross sectional survey data limitation terms data collection critical aspect care able differentiate primary psychiatric disorders intoxication withdrawal induced states whether treating clearly defined co occurring disorders makes difference outcome review looked issue treating co occurring mood disorders substance use disorders authors conclude mood stabilization possible lead decreased substance use typical flow diagram diagnosis might proceed patients co occurring disorders illustrated figure little literature treating demarcated disorders clinical practice intoxication withdrawal substance induced states may difficult determine outpatient setting number problematic scenarios purely psychiatric perspective difficult treat severe anxiety bipolar disorder chronic refractory insomnia primary diagnosis psychiatric diagnosis established anxiety depression disorders occur one substance use disorders approached systematic manner need long term use benzodiazepines rare happen low frequency current practice estimate admissions residential care substance use disorders one main problems using benzodiazepines advances evidence based use populations sud determined addiction risk potent short acting benzodiazepines presented higher risk much research done since major guidelines sleep substance use disorders include guidance specific use previously mentioned guidelines treating sleep anxiety disorders context addiction apa guideline cautions years old considered reflect current knowledge practice minimal relevant clinical benzodiazepine related research since guidelines available provide detailed discussion approach prescription overall handling controlled substances applied benzodiazepines guideline contains number checkpoints system care assessment treatment patient prescribing plan includes detailed informed consent discussion goals duration treatment specific indication instructions patient british national formulary also provides basic guidance responsibilities prescriber controlled substances three basic areas suggested include drug given sound medical reason dose escalated physician become unwitting source supply addicts structured approach prescribing benzodiazepines may useful evidence significant interpersonal component study general practitioners found overwhelmed psychosocial problems patients prescriptions driven wanting help patient additional biases noted study limited availability psychological services personal use benzodiazepines stress relief perceiving benzodiazepine benign time constraint counseling physician follow meta synthesis studies benzodiazepine prescribing authors synthesized findings qualitative studies found ambivalent attitudes long term benzodiazepine prescribing characterized decisions complex demanding uncomfortable decisions varied individual physician times interaction patient attributes physician values influenced prescribing decision decisions complex demanding setting substance use disorder patient may seeing physician get prescription use primarily get intoxicated treat effects primary addiction potentiate effects another addictive drug complicated original prescription made different physician patient asking refill i included list practical tips interpersonal dimension details useful optimizing safe prescription benzodiazepines table population george dawson md dfapa references arthur hughes matthew r williams rachel lipari jonaki bose rti international elizabeth p copello larry kroutil prescription drug use misuse united states results national survey drug use health samhsa september cousins dh gerrett warner review medication incidents reported national reporting learning system england wales years br clin pharmacol oct warner trinidad jp bastian ba et al drugs frequently involved drug overdose deaths united states national vital statistics reports vol hyattsville md national center health statistics sun ec dixit humphreys k darnall bd et al association concurrent use prescription opioids benzodiazepines overdose retrospective analysis bmj paulozzi lj strickler gk kreiner pw koris cm controlled substance prescribing patterns prescription behavior surveillance system eight states morbidity mortality weekly report mmwr october janicak pg marder sr pavuluri mn principles practice psychopharmacology th ed philadelphia pa lippincott williams wilkins bandelow baldwin ds pharmacotherapy panic disorder stein dj hollander rothbaum bo eds textbook anxiety disorders nd ed arlington va american psychiatric publishing inc van ameringen mancini patterson simpson truong pharmacotherapy generalized anxiety disorder stein dj hollander rothbaum bo eds textbook anxiety disorders nd ed arlington va american psychiatric publishing inc short long term use benzodiazepines patients generalized anxiety disorder review guidelines internet ottawa canadian agency drugs technologies health jul available ncbi nlm nih gov books nbk lai hm cleary sitharthan hunt ge prevalence comorbid substance use anxiety mood disorders epidemiological surveys systematic review meta analysis drug alcohol depend sep grant bf saha td ruan wj goldstein rb chou sp jung zhang smith sm pickering rp huang hasin ds epidemiology dsm drug use disorder results national epidemiologic survey alcohol related conditions iii jama psychiatry jan pettinati hm o'brien cp dundon wd current status co occurring mood substance use disorders new therapeutic target psychiatry jan sateia mj buysse dj krystal ad neubauer dn heald jl clinical practice guideline pharmacologic treatment chronic insomnia adults american academy sleep medicine clinical practice guideline clin sleep med available aasmnet org resources pdf pharmacologictreatmentofinsomnia pdf american psychiatric association practice guideline treatment patients substance use disorders nd edition american psychiatric association practice guidelines treatment psychiatric disorders compendium arlington va american psychiatric association pp available online psych org psych pract treatg pg sudepg pd national institute health care excellence nice controlled drugs safe use management london uk national institute health care excellence nice apr p nice guideline available https guidelines gov home disclaimer id contenttype fulltextlink redirect https f fwww nice org uk fguidance fng british national formulary published jointly pharmaceutical press division royal pharmaceutical society east smithfield london ew aw uk bmj group tavistock square london wch jk uk p anthierens habraken petrovic christiaens lesser evil initiating benzodiazepine prescription general practice qualitative study gps perspectives scand prim health care dec sirdifield anthierens creupelandt chipchase sy et al general practitioners experiences perceptions benzodiazepine prescribing systematic review meta synthesis bmc fam pract dec table selected benzodiazepine benzodiazepine like compounds allosteric modulators gabaa receptor benzodiazepines alprazolam lorazepam clonazepam diazepam chlordiazepoxide temazepam benzodiazepine like imidazopyridines zolpidem cyclopyrrolone eszopiclone pyrazolopyrimidine zaleplon table use benzodiazepines patients substance use disorders acute subacute detoxification benzodiazepines remain drugs choice alcohol sedative hypnotic detoxification many treatment facilities withdrawal protocols use anticonvulsants phenobarbital benzodiazepines widest safety margin may address symptoms withdrawal syndrome like anxiety better non benzodiazepine options benzodiazepines long half lives generally preferable agents familiarity options patients severe liver disease also necessary short term bridging effective long term plan treating anxiety anxiety depression withdrawal syndromes patients chronic complicated history use difficult treat textbook scenarios based pharmacological properties medications used many situations difficult know withdrawal syndrome adequately treated whether underlying anxiety sleep disorder surfacing whether new substance induced disorder combination processes short term bridging case polypharmacy situation alternative medications less safe many non benzodiazepine medications used treat depression sleep anxiety disorders risk polypharmacy environment common flag problems cardiac conduction many situations best avoid medications target patient anxiety insomnia potentially complicate problems use benzodiazepines temporarily acute catatonia agitation akathisia transient anxiety due brief severe stressors residential treatment centers agitation likely associated complex withdrawal states include severe anxiety states benzodiazepines useful medications alleviate akathisia result treatment ssris antipsychotic medications long term severe treatment refractory insomnia severe treatment refractory anxiety disorders including mixed anxiety bipolar states mixed anxiety depressed states situations abuse potential dose escalation multiple prescribers additional illegal intoxicants contained table tips benzodiazepine prescribing interpersonal dimension avoid emotional prescribing based stress situation patient characteristics well thought general approach prescribing deviate plan aware prescribing controlled substance affect decision making relationship patient maintain conservative prescribing bias general especially case suspected substance use disorder based risks scenarios presented maintain teaching role patient includes detailed risk benefit discussion rational prescribing prescribing benzodiazepine includes informed consent discussion addiction risk prevent consult colleagues difficult situations avoid professional isolation solicit feedback colleagues would make similar decisions group practices controlled substance prescribing basis quality improvement initiative process technical considerations carefully assess patients requesting treatment benzodiazepines especially new practice diagnosis treated rationale needs clear reevaluating diagnosis response therapy time equally important consider urine toxicology search drugs especially compounds often used benzodiazepines methadone opioids alcohol stimulants benzodiazepine prescribed urine toxicology also confirms adherence rather diversion consult prescription drug monitoring program pdmp rules vary state states require checking pdmp prescription controlled substance consult collateral contacts know patient well patient structured environment know procedures monitoring dispensing medication clear plan indication benzodiazepine including plan discontinuing discuss patient time initial prescribing decision written document expectations patient may good idea anchor point treatment although treatment contracts necessary improve outcomes expectations terms single prescriber precautions expected outcomes must avoided generally better rushed conversation topics document reference point future decisions close monitoring generally necessary collateral contacts assure patient well experiencing complications benzodiazepine important consideration collateral information patient functional capacity medication dose escalation early sign problem prescriptions counted pill counts visit determine rate patient taking medication develop referral patterns non pharmacological approaches problems commonly addressed benzodiazepines like insomnia referral cbt sleep chronic pain pain specialist physical therapy referrals supplementary link final psychiatric times version article